Live Breaking News & Updates on Invizius Limited

Stay updated with breaking news from Invizius limited. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Invizius's Pioneering Dialysis Product H-Guard® Completes First In-Human Clinical Study

Study demonstrated safety and tolerability of H-Guard®, a second generation complement regulator, designed to address serious immune system-driven complications of dialysis.Encouraging biomarker data positions H-Guard for upcoming Acute Kidney Injury (AKI) trial focused on reducing complement mediated renal tubu. ....

United Kingdom , Sandip Mitra , Duha Ilyas , Ilyas Duha , Magnus Nicolson , Leonard Ebah , Professor Of Renal Medicine At Manchester University , Care Research , Manchester Clinical Research Facility , National Institute For Health , Invizius Limited , Manchester University , Acute Kidney Injury , Continuous Renal Replacement Therapy , National Institute , Priming Solution , Manchester Royal Infirmary , Professor Sandip Mitra , Intensive Care Unit , Chronic Kidney Disease , Chief Executive Officer , Professor Mitra , Consultant Nephrologist , Renal Medicine , Stockholm May ,

Invizius Announces Appointment of World-Renowned Nephrologist Professor Bernard Canaud to its Clinical Advisory Board

/PRNewswire/ Invizius Limited ("Invizius"), a biotechnology company developing breakthrough treatments for patients on dialysis, is pleased to announce the. ....

United States , United Kingdom , Glasgow City , City Of , Richard Boyd , Jonathan Milner , Karolinska Institutet , Bernard Canaud , Candy Herbert , Regulatory Agency , Pennsylvania Convention Center , Invizius Limited , International Society Of Nephrology , University Medical Centre Groningen , American Society Of Nephrology , University Of Manchester , Edinburgh University Old College Capital , Montpellier University School Of Medicine , University Of Heidelberg , French Society Of Nephrology , University Of Strathclyde , University Of Oxford , Professor Bernard Canaud , Clinical Advisory , Emeritus Professor , Montpellier University School ,

Final Results

Thames Ventures VCT 2 PLCLEI: 21380035MV1VRYEXPR9531 July 2023Final Results for the year ended 31 March 2023 31 March 202331 March 2022 PencePence Ventures Share pool Net Asset Value per. ....

United Kingdom General , United Kingdom , United States , City Of , Republic Of Ireland , Panmure Gordon , Companies House , Trinny London , Royal Bank , Lignia Wood Company , Virtual Class Limited Third Space , Vibrational Research , Ayar Labs Inc , Channel Mum , Maverick Pubs Holdings , Company At St , Cap Growth Fundb Accum , Virtual Class , Live Better With , Masters Of Pie , Blackrock Cash Fund Class , Carbice Corporation , Health Works , Foresight Group , Venture Capital , Service Saa ,

Invizius Announces Appointment of Peter Stenvinkel, Professor of Nephrology at Karolinska Institutet, to the Clinical Advisory Board

/PRNewswire/ Invizius Limited ("Invizius"), a biotechnology company developing treatments to suppress unwanted immune responses in haemodialysis, is pleased. ....

Glasgow City , United Kingdom , City Of , Jonathan Milner , Karolinska Institutet , Vifor Pharma , Richard Boyd , Peter Stenvinkel , Sandip Mitra Manchester , International Society Of Renal Nutrition , Reata Pharmaceuticals , Old College Capital , Zealand Society Of Nephrology , Professor Paul Barlow University Of Edinburgh , International Society Of Nephrology , University Of Edinburgh , Nobel Assembly At Karolinska Institutet , National Kidney Foundation , Karolinska University Hospital , Society Of Nephrology , European Renal Association , Invizius Limited , Fresenius Medical Care , Professor Peter Stenvinkel , Clinical Advisory , Professor Stenvinkel ,

Invizius Closes £5.3M Series A Financing

Invizius Limited, a Motherwell, Scotland, UK-based biotechnology company developing treatments to suppress unwanted innate immune responses, closed Series A financing of £5.3m.
The round was led by existing investors Mercia, Downing Ventures, Old College Capital, Scottish Enterprise, Solvay Ventures and new investors Calculus Capital and experienced life science entrepreneur and investor, Dr Jonathan Milner. The Series A remains open to other investors until June 2021.
The company intends to use the funds to complete a First-in-Man safety study in 2022 of its H-Guard
® Priming Solution to reduce the life-threatening inflammatory effects of haemodialysis.
Led by Richard Boyd, Chief Executive Officer, Invizius is a late pre-clinical-stage biotechnology company developing treatments to suppress unwanted innate immune responses, focused initially on reducing the life-threatening inflammatory effects of dialysis. Founded in 2017, the University of Edinburgh� ....

United States , United Kingdom , City Of , Jonathan Milner , Richard Boyd , Old College , University Of Edinburgh , Invizius Limited , United Kingdom Based , Downing Ventures , Scottish Enterprise , Solvay Ventures , Calculus Capital , Priming Solution , Chief Executive Officer , North America , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , நகரம் ஆஃப் , ஜொனாதன் மில்னர் , ரிச்சர்ட் பையன் , பழையது கல்லூரி , பல்கலைக்கழகம் ஆஃப் எடின்பர்க் , ஒன்றுபட்டது கிஂக்டம் அடிப்படையிலானது , வீழ்ச்சி முயற்சிகள் , ஸ்காட்டிஷ் நிறுவன ,